New Alzheimer’s Drugs Don’t Deserve the Hype (Being Patient):
A prominent childhood memory is of my grandparents living with and then dying from dementia. As is universal wi… Read More
For the first time, people worried about their risk of Alzheimer’s disease can go online, order a blood test, and receive results in the privacy of their homes.
This might seem appeali… Read More
The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and a precursor condition, mild cognitive impairment. Medicare has said it will pay for… Read More
Data from the CLARITY trial earlier this year was supposed to be the crowning glory of the amyloid hypothesis, vindication for proponents of this long-held but much-maligned theory of Alzhei… Read More
The real costs of the new Alzheimer’s drug, Leqembi — and why taxpayers will foot much of the bill (CBS News):
The first drug purporting to slow the advance of Alzheimer’s… Read More
Welcome to a new edition of SharpBrains e‑newsletter, featuring this time a range of interventions for brain/ cognitive/ mental health plus a few brain teasers to test our perception a… Read More
The War Over Whether Medicare Should Pay For The New Anti-Alzheimer’s Drugs (Forbers):
The powerful Alzheimer’s Disease lobby is fighting a multi-billion-dollar battle on two fro… Read More
Jan. 6, 2023 — The extremely anticipated Alzheimer’s drug lecanemab was granted accelerated approval status this afternoon by the FDA, providing hope the place there was… Read More